Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Stock Short Interest Jumps 11,467.5%

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) was the recipient of a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 31,478,314 shares, a growth of 11,467.5% from the August 31st total of 272,128 shares. Based on an average trading volume of 1,150,992 shares, the short-interest ratio is presently 27.3 days. Approximately 2.7% of the shares of the stock are short sold.

Insiders Place Their Bets

In other news, Director Roberto Mignone sold 367,600 shares of the company’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Brian Savage sold 7,342 shares of the stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the sale, the insider owned 8,500 shares of the company’s stock, valued at $330,225. This trade represents a 46.35% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 374,959 shares of company stock worth $14,644,285 over the last quarter. Company insiders own 0.54% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TEVA. Norges Bank acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at about $1,098,060,000. WCM Investment Management LLC grew its holdings in shares of Teva Pharmaceutical Industries by 191.4% during the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after buying an additional 26,813,522 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd grew its holdings in shares of Teva Pharmaceutical Industries by 18.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after buying an additional 5,917,423 shares in the last quarter. Castle Hook Partners LP acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $82,013,000. Finally, Capital World Investors acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $73,687,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $40.18 on Friday. The company has a market cap of $46.82 billion, a PE ratio of 66.97, a PEG ratio of 4.93 and a beta of 0.87. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56. Teva Pharmaceutical Industries has a 1 year low of $18.21 and a 1 year high of $40.79. The company’s 50-day moving average is $36.04 and its two-hundred day moving average is $33.76.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The company had revenue of $4.14 billion during the quarter. Equities analysts anticipate that Teva Pharmaceutical Industries will post 1.94 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on TEVA shares. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Wall Street Zen lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Oppenheimer initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday. They set an “outperform” rating and a $50.00 price target on the stock. Leerink Partners assumed coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price objective on the stock. Finally, Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research report on Tuesday, July 28th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $43.73.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.